Breaking News, Collaborations & Alliances

Huahui Health, BeOne Medicines Partner to Advance Oncology Drug HH160

Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide.

Author Image

By: Charlie Sternberg

Associate Editor

Huahui Health has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy. Under the agreement, BeOne Medicines, a global oncology company, is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide. HH160 simultaneously targets PD-1, CTLA-4, and VEGF-A, three clinically validated targets in cancer immunotherapy and anti-angiogenesis....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters